Imagion Biosystems Limited Disclosure and Communications Policy

Apr 22, 2018
Posted in: Investor updates

Home » Imagion Biosystems Limited Disclosure and Communications Policy

Imagion Biosystems Limited Disclosure and Communications Policy

Apr 22, 2018
Posted in: Investor updates

Imagion Biosystems Limited (Company) is committed to the objective of promoting investor confidence and the rights of shareholders.
Read the Imagion Biosystems Limited Disclosure and Communication Policy.

Positive independent review sets priority path to market for MagSense® Technology

February 5, 2023

Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance

Quarterly Activity Report – Quarter Ending 31 December 2022

January 30, 2023

Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with

Quarterly Activity Report – Quarter Ending 30 September 2022

October 28, 2022

Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Imagion Biosystems Limited Disclosure and Communications Policy

Imagion Biosystems Limited Disclosure and Communications Policy

Related Articles

Positive independent review sets priority path to market for MagSense® Technology

Quarterly Activity Report – Quarter Ending 31 December 2022

Quarterly Activity Report – Quarter Ending 30 September 2022

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list